Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1.

There were also strong trends for association of vedolizumab treatment (vedolizumab vs placebo, OR = 9.346; p = 0.0605) and disease duration (“short” [≤2 years] vs “long” [>2 years], OR = 2.660; p = 0.0531) with achieving the primary endpoint that approached but did not reach statistical significance ( Figure 3 ).

also in 111,027 other papers